CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation

Blood

Volumn 95, Issue 4, 2000, Pages 1502-1505

  Kuehnle, Ingrid ^a   Huls, M Helen ^a   Liu, Zhensheng ^a   Semmelmann, Micah ^a   Krance, Robert A ^a   Brenner, Malcolm K ^a   Rooney, Cliona M ^a   Heslop, Helen E ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; MESNA; MONOCLONAL ANTIBODY; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CHILD; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0034651548     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1502.004k40_1502_1505     Document Type: Article

References (23)

1. Heslop HE, Rooney CM. Adoptive immunotherapy of EBV lymphoproliferative diseases. Immunol Rev. 1997;157:217.
2. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195.
3. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood. 1998;91:3654.
4. Gerritsen EJ, Stam ED, Hermans J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant. 1996;18:377.
5. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185.
6. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994;331:679.
7. Rooney CM, Smith CA, Ng C, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet. 1995;:345:9.
8. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med. 1996;2: 551.
9. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549.
10. Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol. 1997; 9:702.
11. Gottschalk S, Ng CYC, Perez M, Brenner MK, Heslop HE, Rooney CM. Mutation in EBV produces immunoblastic lymphoma unresponsive to CTL immunotherapy [abstract]. Blood. 1998;92 (suppl 1):321a.
12. Fischer A, Blanche S, LeBidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991;324:1451.
13. Mahmoud H, Brenner M, Rooney C, Heslop H, Krance R. Anti-CD21 and CD24 monoclonal antibodies (Anti-CD21/24) for B-cell lymphoproliferative disease (LPD) following bone marrow transplantation (BMT) [abstract]. Blood. 1993;82(suppl 1):636a.
14. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90: 2188.
15. Leget GA, Czuczman MS. Use of rituximab, the new PDA-approved antibody. Curr Opin Oncol. 1998;10:548.
16. Hongeng S, Krance RA, Bowman LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukemia. Lancet. 1997;350:767.
17. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Br J Haematol. 1995;89:98.
18. Heslop HE, Brenner MK, Rooney CM, et al. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994;5:381.
19. Faye A, Van Den Abeele T, Peuchmaur M, Matheu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet. 1998;352:1285.
20. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5:611.
21. Hale G, Waldmann H, for CAMPATH users. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. Blood. 1998;91:3079.
22. Gross TG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant. 1999;23:251.
23. Cavazzana-Calvo M, Bensoussan D, Jabado N, et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. Br J Haematol. 1998;103:543.